Drug Trial Radar · NCT05132777
Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
155
Planned (sponsor's estimate)
Start
Nov 20, 2021
Primary completion
Sep 30, 2023
Study completion Sep 30, 2024
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- First posted
- Nov 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase II, open label, multi-center study to evaluate the efficacy and safety of JMT101 combined with Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- EGFR Exon20 Insertion Mutations
Interventions
JMT101Drug
JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
Osimertinib Mesylate TabletsDrug
Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Objective Response Rate (ORR) Assessed by Blinded Independent Review Committee (IRC) per RECIST Version 1.1Time frame: From the first dose to disease progression or end of study, an average of 1 year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.